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With aging, melanocytes become u]nevenly distributed 
in the epidermis. In light skin individuals, hypo­
pigmentation is found in association with focal hyper­
pigmentation (lentigo senilis). Apparently this results 
from progressive loss of active melanocytes and focal 
increase in melanocyte proliferation alnd/ or aggregation. 
This paper summarizes the present knowledge on aging 
of melanocytes in vivo and in vitro, with a focus on the 
role of melanin as a determinant for proliferation and 
terminal differentiation. We describe that excessive 
melanin deposition by cyclic AMP-inducing agents 
results in increased expression of the cyclin-dependent 
kinase inhibitors p27Kip-l and p21 sm-lIwaf-l, increased 
binding of p16 to CDK4, and terminal differentiation. 
AGING OF MELANOCYTES IN THE SKIN 
Reports from the last four decades have documented that there is a 
gradual decrease in the nwnber of dyhydroxyphenylaIanine-positive 
melanocytes in the integument of young versus old individuals (Szabo, 
1954; Staricco and Pinkus, 1957; Snell and Bisc:hnitz, 1963; Fitzpatrick 
et aI, 1964; Gilchrest et aI, 1979; Nordlund, 1986). Independent of skin 
color, the number of a-dyhydroxyphenylalaniine-positive melanocytes 
decreases from 8% to 20% per decade after 30 y of age (Nordlund, 
1986; Herzberg and Dinehardt, 1989). 
With aging, melanocytes in the skin become a mosaic population 
manifested by the appearance of large and small melanocytes; the skin 
becomes mottled and the ability to tan is also reduced (Montagna and 
Carlisle, 1990). Paradoxically, despite a decrea;se of active melanocytes, 
older skin has irregular pigmentation frequentlly associated with hyper­
pigmentation. It has been postulated that this heterogeneity in skin 
pigmentation results from uneven distribution of pigment cells, greater 
a-dyhydroxyphenilaIanine positivity in sun-exposed areas of the skin 
(Gilchrest et ai, 1979), a local loss of melanoc:ytes, and a modification 
in the interaction between melanocytes and keratinocytes (Ortonne, 
1990). Solar lentigines, which appears in sUIl-exposed areas, is con­
sidered to be a hallmark of older skin. Electron-microscopic analysis 
of these lesions has shown an increase in melanocyte number above 
the dermo-epidermal junction and has also increased melanosomal 
complexes in surrounding keratinocytes (reviewed by Ber Rahman 
and Bhawan, 1996). Presenciy, little or nothing is known about the 
genesis, proliferative potential, and evolution of these lesions. 
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Importantly, the efficiency with which the melanocytes 
exit the cell cycle depends on the melanin background 
of the donor's cells. Melanocytes from skin types IV-VI 
that accumulate large amounts of brown black melanin 
(eumelanin), lose expression of the transcription factors 
E2Fl and E2F2, two key regulatory proteins, and with­
draw from the cell cycle more rapidly than melanocytes 
from skin types I and IT that accumulate red/yellow 
melanin (pheomelanin). Thus, we propose that terminal 
differentiation is a tumor suppressor mechanism that 
becomes less efficient under imperfect eumelanization. 
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Normal pigmentation during wound healing is also affected by age. 
Older individuals have poorly pigmented, healed wounds that are 
probably more susceptible to ultraviolet damage (West, 1994). Melanin 
synthesis in the hair bulb is also lost in senile hair. Apparently, 
melanocytes are still present in the outer root sheath, but they have 
lost their differentiated phenotype and became amelanotic (Takada 
et aI, 1992). Interestingly, although the number of active melanocytes 
decreases with age, transplanted human skin from old individuals to 
immunodeficient mice causes a notable increase in the nwnber of Or­
dyhydroxyphenilalanine-positive melanocytes in the skin grafts (Gilhar 
et aI, 1991). This suggests that in old skin either there are dormant, 
inactive, melanocytes that under the strong stimuli of an inflammatory 
response, such as skin transplantation, can become active, or there is a 
reservoir of nonproliferating melanocytes able to re-enter the cell cycle 
and actively proliferate. Understanding how old melanocytes respond 
to grafting could have important implications for re-pigmenting old 
skin and perhaps for pigmentary disorders such as vitiligo. 
It has been demonstrated that monkey choroidal melanocytes, 
considered to be terminally differentiated melanocytes, have extensive 
alterations with age in melanosomes, the specialized organelles in which 
melanin is synthesized and deposited (Hu, 1979). During aging the 
meIanosomes acquire vacuoles filled either completely or partially with 
homogenous material onow electron density. Some melanosomes fuse 
together as a melanosome complex enclosed by a unit membrane, and 
with increasing age the number of melanosomes with alterations 
increases from 10% to 15% at age 7, to 50% at age 13, and to greater 
than 60"04 at age 15. It remains to be determined if similar changes 
occur in human melanocytes during aging. 
Epidemiologic studies have also demonstrated age-related changes 
in melanocytic nevi. With increased age, there is a progressive decrease 
in the number of these benign lesions (Ortonne, 1990). Over the 
course of several years epidermal nevus cells appear to follow a pathway 
of migration to the dermis and differentiation (Clark et ai, 1984; Aso 
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et ai, 1988). Because in the dennis the nevus cells loose the expression 
of melanocyte markers, it is presently unknown if the nevus cells 
remain in the dermis or if they are eventually removed by phagocytosis 
or apoptosis. 
AGING OF MELANOCYTES AND NEVUS CELLS IN VITRO 
Normal human cells in culture are programmed to undergo 
irreversible functional decrements that mimick age changes in the 
whole organism (Hayflick, 1979) .  The limited proliferative potential 
in culture has been tenned replicative senescence. One of the 
manifestations of replicative senescence that may have profound 
implications in vivo is the loss of the differentiated function of aged 
cells (Campisi, 1996). Senescent human fibroblasts switch from 
matrix-producing to matrix-degrading cells: they overexpress colla­
genase and underexpress collagenase inhibitors, which may contribute 
to collagen breakdown and thinning of the dermis as observed in vivo. 
In addition, expression of tissue-type plasminogen activator is increased 
in human senescent fibroblasts (West et al 1996). The plasminogen 
activators are regulators of extracellular proteolysis, therefore over­
expression of tissue-type plasminogen activator may also contribute to 
progressive disruption of extracellular matrix maintenance. 
Although enormous progress has been made in. understanding the 
biochemical and molecular mechanisms of pigmentation (reviewed by 
Hearing, 1998), and pigmentary disorders such as piebaldism (Hosoda 
et aI, 1994) and Wardenburg syndrome (Tassabehji et aI, 1994), the 
molecular analysis of the life cycle of the normal melanocyte is still in 
its infancy. We and others have demonstrated that the number of 
population doublings achieved by human melanocytes exposed to 
mitogens such as phorbol esters and fibroblast growth factor depends 
on the age of the donor (Gilchrest et ai, 1983; Abdel-Malek et aI, 
1994; Medrano et aI, 1994). Melanocytes from neonatal skin undergo 
60-80 population doublings (PD), whereas cells from adults from 20 
to 50 y of age proliferate much more slowly and have fewer PD. We 
have been unable to obtain proliferating cell cultures from donors over 
60 y of age. Additionally, melanocytes derived from a Wemer's 
syndrome patient (a premature aging disease) have a dramatically 
reduced proliferative life-span compared with aged matched controls 
(2-3 PD versus 15-20 PD) (Medrano, unpublished results). This is of 
particular interest because one of the clinical manifestations of We mer's 
syndrome is early graying of the hair, mottled pigmentation of the 
skin, and high frequency of melanomas (Goto et ai, 1996), thus 
melanocytes in these patients may be particularly susceptible to 
mutations. The Wemer's gene has been found to codit)r for a RecQ­
type DNA helicase (Yu et ai, 1996). DNA helicases unwind duplex 
DNA involved in replication, recombination, repair, and transcription. 
Chromosomal instability is a characteristic symptom shared by helicase­
associated diseases (Ellis, 1996). Therefore, understanding the biologic 
role of Wemer's helicase may be of potential interest for pigment 
cell biology. 
Melanocytes isolated from nonnal nevi have a greater variability in 
their in vitro life-span compared with nonnal epidermal melanocytes 
from age-matched donors (Graeven and Herlyn, 1992; Medrano, 
unpublished results). Some cultures undergo more than 20 PD, whereas 
others proliferate well for only 6--10 PD before entering replicative 
senescence. Hypotheses for such variability include increased genetic 
instability andlor the presence of different histologic lesions; however, 
it is likely that the low number ofPD attained by some nevi melanocytes 
may reflect the clonal origin of the cells that might have expanded to 
have a sizeable number in vivo, and therefore had only a limited 
number of PD to grow in vitro, before reaching senescence. 
Role of the a-lIlelanotropic hOrlIlone and the cyclic adenosine 
mono-phosphate (cAMP) pathway in lIlelanization and 
tenninal differentiation The development of mouse melanocytes 
from neural crest stem cells is known to require a cascade of specific 
growth factors .. It has been demonstrated that fibroblast growth factor 
2 specifies the melanocyte lineage and that steel factor and endothelin 
3 regulate selection and proliferation of melanocyte progenitors. In 
addition, endothelin 3 stimulates the differentiation of these cells to a 
mature, pigmented melanocyte. Finally, upregulation of pigmenta-
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Figure 1. Activation of the cAMP pathway melanization and terminal 
differentiation. (A) The cartoon depicts a simplified cAMP pathway and 
molecular targets for a-MSH, cholera toxin, and forskolin. (B) Incorporation 
of BrdU in actively proliferating melanocytes . (C) Incorporation ofBrdU after 
4 wk in the differentiating medium. Only a few cells are able to incorporate 
BrdU in tenninally differentiated, pigmented melanocytes. The cells were fixed 
with 70% ethanol and incubated with anti-BrdU antibody for 30 min at 37°C. 
After washing cells were incubated with an anti-mouse alkaline phosphatase­
conjugated secondary antibody as described by the manufacturer (Boehringer, 
Indianapolis, IN). 
tion is attained by the action of a-melanocyte stimulating hormone 
(a-MSH) (Murphy et ai, 1997). 
Human epidermal melanocytes also respond to mitogens that target 
the cAMP pathway, such as a-MSH (Abdel-Malek e/ ai, 1995), cholera 
toxin (Gilchrest et ai, 1984; Halaban et ai, 1988; Herlyn e/ ai, 1988; 
Abdel-Malek et ai, 1992; Medrano et ai, 1 994), forskolin (Haddad and 
Medrano, unpublished results), dibutyryl-cAMP (Halaban, 1988), and 
methylxanthines, by increasing melanin production and melanosome 
aggregation. These agents have different molecular targets in the cAMP 
pathway, including the MC1R receptor for a-MSH, a Ga protein for 
cholera toxin, and adenylate cyclase itself in the case of forskolin 
(Fig lA). Subsequently, the enzyme adenylate cyclase is activated with 
accumulation of the second messenger cAMP ; however, it is still not 
clear what genes are activated downstream of the cAMP cascade that 
will eventually result in increased proliferation and melanization. 
It is interesting that melanocytes from different skin types show 
dissimilar rates of proliferation and levels and types of melanin accumu­
lated in response to a-MSH (Hunt et ai, 1996; Haddad et ai, 1998). 
This may be explained in part by the presence of allelic variants of the 
MC1R that may induce a less potent signaling cascade or even result 
in complete unresponsiveness to the melanotropic honnone (Hunt 
et ai, 1996). MC1R variants with loss of function are found in some 
individuals with red hair, although red hair can still be found in 
individuals with a normal MC1R. Unlike a-MSH, cholera toxin does 
not activate the MCIR (Fig lA), but, as we will demonstrate in this 
communication, melanocytes exposed to this agent still show a high 
degree of variability in both proliferation and melanization. This 
indicates that only a fraction of the very complex pathway of human 
pigmentation is presently understood and much is left to be discovered. 
We have found that in response to cholera toxin, or a-MSH, 
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melanocytes from skin types IV-VI accumulate high levels of brown/ 
black melanin. This eventually results in loss of the proliferative capacity 
of the heavily pigmented melanocytes (Abdel-Malek et aI, 1 994; 
Medrano et aI, 1994; Haddad and Medrano, unpublished results). 
Figure 1(B) shows that, initially, most of the melanocytes respond to 
the cAMP inducer by increasing their proliferation rates, as shown by 
their ability to incorporate the thymidine homolog bromo-deoxyurid­
ine (BrdU) into DNA. The continuous culture with cholera toxin, 
however, results in only a small number ofBrdU-positive cells (Fig 1 C). 
Thereby high melanin levels result in loss of the proliferative capacity, 
when the cells still have potential for many more rounds of cellular 
division. Operatively, we refer to these quiescent melanocytes as 
terminally differentiated cells (Medrano et ai, 1994). Similar results 
have been obtained with mouse and human melanoma cells after 
induction of hyperpigmentation by treatment with millimolar concen­
trations of the amino acid I-tyrosine, a precursor in the melanin 
synthesis pathway (Guerra et aI, 1990; RiebeJ[ and Rieber, 1994). An 
early study by Bennett (1983) showed that mouse melanoma cells 
follow a stochastic model for terminal differentiation after the addition 
ofl-tyrosine, and only the nonpigmented cells continue to proliferate. 
EXPRESSION OF CELL CYCLE REGULATORY GENES 
AND MELANINS 
Role of the cyelin-dependent kinase inhibitors The rapid syn­
thesis and degradation of a fumily of proteins known as cyclins, tightly 
regulate progression of mammalian cells through the cell cycle. Cyclins 
constitute the regulatory subunit of another furnily of proteins known 
as the cyclin-dependent kinases (CDK). Recently, it has been demon­
strated that the activity of such kinases can be negatively regulated by 
proteins generically known as the cyclin-dependent kinase inhibitors 
(CDK-I) of which several have been identified (p21Waf-IISDf-1, 
p27KIP-1, p57, p16INK4, and ptS). 
In normal cells, the CDK-I's function is to regulate growth, 
differentiation, and senescence of cells from diverse origin , including 
fibroblasts and keratinocytes (Hara et ai, 1996; Hauser et aI, 1997). In 
particular, pI6 is deleted or mutated in hereditary familial melanomas 
and other cancers in. vivo (reviewed by Sherr and Roberts, 1995). The 
role of the CDK-I in melanocyte biology is complex and still not well 
understood. An example of this is the unexpected expression of p21 
and p27 found in primary invasive melanomas (Breslow thickness 
greater than 0.076 mm) , compared with noninvasive tumors and 
benign nevi (Maelandsmo et aI, 1996; Trotter et ai, 1997; Plowden, 
Orengo, and Medrano, unpUblished results). The presence of high 
levels of p27 and p21 may confer the invasive melanoma cells' slow 
growth and resistance to conventional cancer treatments such as 
chemotherapy and radiation. 
We have found that accumulation of high levels of brown/black 
melanin (eumelanin), after prolonged treatment with cAMP inducers, 
correlates with increased expression of the CDK-I p27Kip1, poor or 
absent CDK-2 activity, increased binding of the CDK-I p16 to CDK4, 
and a modest increase in p21SDI-1IWaf-l levels (Haddad and Medrano, 
unpublished results). 
Analysis of senescent and terminally differentiated melanocytes has 
revealed conunon, as well as distinct, alterations in gene expression. 
Senescent melanocytes have increased p21 and p16 levels but­
not p27, whereas terminally differentiated melanocytes have a large 
increase in p27 levels, a modest increase in p21, and no changes in 
p16 (Fig 2A-C). Terminally differentiated and senescent melanocytes, 
however, have an identical inability to activate and translocate the 
kinase ERKl to the nucleus, compared ,mth young melanocytes 
cultures (Medrano et ai, 1994). Studies in progress aim to resolve 
whether terminal differentiation results in an early senescent phenotype 
in epidermal melanocytes. 
Transcription factors of the E2F family 2lDd melanins The E2F 
consist of five distinct E2F members and at least two heterodimer 
partners, DPI and DP2. The individual family members are able to 
form a variety of protein complexes and may play distinct roles in 
proliferation, cell cycle exit, and terminal differentiation. E2F1, E2F2, 
and E2F3 can efficiently activate DNA synthesis in quiescent fibro-
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Figure 2. p27Kip-l, p21Waf-1/SDI-1, and p16INK4 expression in pro1i£erat­
ing, terminally differentiated, and senescent melanocytes. Equal amounts 
(30 j.lg) of whole cell lysates were electrophoresed in 12% sodium dodecyl 
sulfate polyacrylamide gel slabs and blotted on nitrocellulose membranes. 
Membranes were incubated overnight at 4°C in either of the following 
antibodies: 1:300 dilution of a rabbit anti-p16 (PharMingen, CAl; 1:100 mouse 
anti-p21 (Oncogene Research Products, MA); 1:2000 dilution of a monoclonal 
anti-p27 (Transduction Laboratories), all in T-TBS buffer. Mter washing with 
T-TBS buffer, the membranes were incubated with a donkey anti-rabbit, or a 
sheep anti-mouse antibody, conjugated to hor.;eradish peroxidase (1 :3000). The 
target proteins were detected using the ECL western blotting detection kit 
(Amer.;ham, IL). *Unspecific bands recognized by the p21 and p16 antibodies. 
These bands are shown to demonstrate equal protein loading in the gel. M, 
primary melanoma cells; Y, young proliferating melanocytes; D, tenninally 
differentiated, nonproliferating melanocytes; S, senescent melanocytes. 
blasts, whereas E2F4 and E2F5 have little or no activity in S phase 
induction (DeGregori et ai, 1997). Changes in E2F DNA-binding 
activity are detected during erythroid, adipocyte, muscle, and epithelial 
differentiation (reviewed by Sidle et aI, 1996). E2F4 and E2F5 fonn 
complexes with the p107 and p130 retinoblastoma furnily proteins and 
function as transcriptional repressors in quiescent cells (Smith et ai, 
1996). In particular, E2F-p 1 30 complexes may repress E2F1 and E2F2 
genes by binding to E2F DNA-binding elements ill their own 
promoters. 
We have found that the efficiency with which the melanocytes exit 
the cell cycle depends on the melanin background of the donor's cells 
(Haddad and Medrano, unpublished results). After continued exposure 
to cAMP inducers such as cholera toxin or a-MSH, melanocytes from 
skin types IV-VI accumulate large amounts of melanin compared with 
melanocytes from skin types I and II (Fig 3A). This eventually results 
in reduced or absent expression ofE2F-1 (Fig 3B, Mel IV, arrowheads) 
and E2F2, increased levels of E2F5, and cell cycle exit (Haddad et aI, 
1998). Under the same treatment, however, melanocytes cultured from 
very light skin show high levels of E2F1 (Fig 3B, Mel I) and E2F2, 
and continue to proliferate for at least 6-10 wk (Haddad and Medrano, 
unpublished results). Current experiments are aimed at determining 
how the melanocyte's cell cycle machinery senses and responds to 
melanin accumulation. 
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Figure 3. Accumulation ofbrown/black melanin correlates with reduced 
E2Fl expression. (A) Kinetics of melanin accumulation in naIve melanocytes 
exposed to a medium containing 10 nM cholera toxin. (B) Kinetics of E2Fl 
expression as determined by western blotting. Arrowheads show the decline in 
E2F1 levels after 2 wk in the differentiating medium, which correlate with 
melanin accumulation and the onset of terrnina1 differentiation. Mel I, 
meJanocytes were arbitrarily assigned to this group when they did not accumulate 
appreciable amounts of brown/black melanin and continued to proliferate in 
the differentiating medium for at least 6 wk. Mel IV, melanocytes from skin 
types IV-VI. 
Figure 4. Senescence-associated b-galactosidase (b-Gal) in proliferating 
and terminally differentiated melanocytes. (A) Proliferating melanocytes, 
only 3-4 cells are stained (arrowheads). (B) Terminally differentiated melanocytes, 
most of the cells show intense staining. �-Galactosidase staining was performed 
as described by Dimri et al (1995). 
GETTING THE "BLUES" AT THE END OF THE 
PROLIFERATIVE LIFE-SPAN: CHROMATIN C HANGES, 
HISTONE ACETYLATION, AND WHAT ELSE? 
A biomarker for senescent cells, a pH 6.0 �-galactosidase (SA-�-Gal), 
has been found to be expressed in senescent fibroblasts ill vitro and in 
the human skin of old individuals, and possibly reflects changes in cell 
function that accompany senescence (Dimri et ai, 1995). We have 
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found that, whereas in the proliferating population of melanocytes 
only a few cells are SA-�-Gal positive (Fig 4A), terminally differentiated 
melanocytes have high levels of this enzyme (Fig 4B). This differs 
from the original observation that terminally differentiated cells such 
as keratinocytes do not express SA-�-Gal, although they do become 
positive when entering replicative senescence (Dimri et ai, 1995). SA­
�-Gal, however, is also detected in fibroblasts induced to irreversibly 
withdraw from the cell cycle by treatment with histone deacetylase 
inhibitors such as sodium butyrate and trichostatin A (Ogryzko et ai, 
1996). Therefore it may serve as a marker for various states of terminal 
loss of proliferation in addition to replicative senescence. 
Recent studies have implicated a role for histone acetylation and 
chromatin structure in growth regulation (reviewed by Wade and 
Wolffe, 1997). If expression of SA-�-Gal is a common manifestation 
of sllch changes in aging, then repressive chromatin domains may be 
strong determinants for the loss of the proliferative capacity of terminally 
differentiated melanocytes. The protein p3001CBP, a novel class of 
acetyltransferase, is a chromatin-remodeling £lctor. p300 associates with 
several transcription factors , including the cAMP-responsive element 
binding protein CREB, a transcription factor known to mediate the 
response of hormones that activate the cAMP pathway (Ogryzko et ai, 
1996) and with functional RNA complexes (Nakajima et ai, 1997). In 
addition, p300/CBP binds to the rumor sllppressor p53 (Gu and 
Roeder, 1997) and stimulates its sequence specific DNA-binding 
activity. Therefore, p300lCBP appears to be a master regulator of cell 
function. It will be interesting to determine whether p300lCBP is 
involved in the cAMP/melanin pathway that leads to melanocyte 
terminal differentiation. 
CONCLUSION 
Multiple diverse and redundant molecular changes characterize senes­
cence in mammalian cells (Smith and Pereira-Smith, 1996; Campisi, 
1996). A major challenge will be to decipher which ones cause 
senescence and which ones result from senescence. It is presently 
unknown if mitotically competent melanocytes exist in old human 
skin. Moreover, it is still not known how melanocytes from young 
donors respond to stimuli such as solar radiation and what is the fate 
of these cells. Previous studies aimed at determining rates of proliferation 
of UV-exposed melanocytes are plagued by artifacts resulting from 
considering thymidine incorporation a manifestation of DNA synthesis 
and not DNA repair; however, because normal, nonsun-exposed skin 
melanocytes are usually in a nonproliferative state, it is difficult to 
hypothesize that melanocytes can exhaust their proliferation capacity 
during the normal life-span of the individual. But, in order to develop 
strategies for intervention therapies for improving the human pigment 
cells in old skin it will be necessary to first understand how melanocytes 
age in the skin. 
Mter exposure to solar radiation or ultraviolet Blight, keratinocytes 
and melanocytes synthesize and release (X-MSH (Farooqui et ai, 1993; 
Chakarborty et ai, 1995; Luger et ai, 1997). Because variants of the 
MCl Receptor have been identified as a risk factor for melanoma 
susceptibility (Valverde et ai, 1996), we hypothesize that delayed 
terminal differentiation in melanocytes unable to accumulate brown! 
black melanin may result in excessive proliferation, contribute to the 
formation of solar lentigines, and increase the risk of immortalization 
of these cells . 
We propose that terminal differentiation is a tumor suppressor 
mechanism only partially operative under imperfect eumelanization. 
Presently it is not known if a similar pathway operates ill vivo, but 
heterogeneity in skin pigmentation and in particular the presence of 
lentigo senilis with aging, and increased frequency of melanomas, in 
individuals from light skin backgrounds, suggest that this might be 
the case. 
Note added in proof: After submitting this manuscript, Bertolotto et a1. (Mol 
alld Cell Bio/18; 694-702, 1998) reported that cAMP increases rnicropthalrnia 
(MITF) expression and binding to tyrosine-related protein 1 (TRP1) and 
TRP2 promoters. 
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